The Medicines Company v. Mylan, Inc., No. 15-1113 (Fed. Cir. Apr. 6, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

The Medicines Company (“ Medicines”) is the owner of U.S. Patent Nos. 7, 582,727 (“the ’727 patent”) and 7,598,343 (“the ’343 patent”). In response to an Abbreviat- ed New Drug Application (“ANDA”) submitted by Mylan, Inc. (“Mylan”), Medicines filed suit in th e United States District Court for the Northern District of Illinois alleging that Mylan’s ANDA infringed claims 1–3 , 7–10, and 17 of the ’ 727 patent, and claims 1–3 and 7–11 of the ’343 patent. Mylan counterclaimed seeking a declaration that the asserted claims were invalid.